C2i Genomics

New York, NY/IsraelLife SciencesCohort: 2019-2020

C2i Genomics is developing a platform to detect and monitor tumor lesions in a patient’s standard blood sample, thus enabling rapid treatment decision-making based on real-time information. The technology leverages proprietary mathematical inference models and machine learning techniques, which provide quantification of circulating tumor DNA with 100X higher sensitivity than current methods.